代谢综合征与长效注射抗精神病药物的关系:系统综述

IF 2.5 4区 医学 Q2 PSYCHIATRY
TTK Nguyen , C McDonald , B Hallahan
{"title":"代谢综合征与长效注射抗精神病药物的关系:系统综述","authors":"TTK Nguyen ,&nbsp;C McDonald ,&nbsp;B Hallahan","doi":"10.1016/j.ejpsy.2022.01.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Objectives</h3><p>Long-acting injectable (LAI) antipsychotics<span><span> increase patient adherence, reduce relapse rates and facilitate regular interaction with community mental health teams. Antipsychotics are however associated with adverse effects including </span>metabolic syndrome<span>. This review outlines the rates of monitoring for and rates of metabolic syndrome in patients treated with LAI antipsychotics.</span></span></p></div><div><h3>Methods</h3><p>We searched Medline, EMBASE, and Cochrane for Medical Subject Heading (MeSH) terms including metabolic syndrome or MetS and depot or LAI antipsychotics. We included data regarding participants’ clinical characteristics, dose and type of antipsychotics administered, rates of monitoring for- and rates of metabolic syndrome and individual metabolic parameters (body mass index or measure of central obesity, blood pressure, lipid levels, plasma glucose and/or HbA1C levels).</p></div><div><h3>Results</h3><p><span>Six studies were included that evaluated rates of monitoring for- and 39 studies examined rates of metabolic syndrome or individual metabolic parameters. Metabolic parameters were not routinely measured in approximately 75% of patients. Rates of metabolic syndrome ranged between 24.3% and 53.2%, with most studies finding no significant differences between oral and LAIs; however, a more preferable weight and lipid profile was detected with LAIs compared to the oral antipsychotics olanzapine and </span>clozapine. Rates of metabolic syndrome and abnormalities of metabolic parameters were comparable among first- and second-generation and between second-generation LAIs.</p></div><div><h3>Conclusions</h3><p>LAI antipsychotics are associated with high rates of metabolic syndrome but low rates of regular monitoring. A robust screening plan to monitor for metabolic syndrome in individuals treated with LAIs is advised including measurement of individual metabolic parameters.</p></div>","PeriodicalId":12045,"journal":{"name":"European Journal of Psychiatry","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review\",\"authors\":\"TTK Nguyen ,&nbsp;C McDonald ,&nbsp;B Hallahan\",\"doi\":\"10.1016/j.ejpsy.2022.01.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and Objectives</h3><p>Long-acting injectable (LAI) antipsychotics<span><span> increase patient adherence, reduce relapse rates and facilitate regular interaction with community mental health teams. Antipsychotics are however associated with adverse effects including </span>metabolic syndrome<span>. This review outlines the rates of monitoring for and rates of metabolic syndrome in patients treated with LAI antipsychotics.</span></span></p></div><div><h3>Methods</h3><p>We searched Medline, EMBASE, and Cochrane for Medical Subject Heading (MeSH) terms including metabolic syndrome or MetS and depot or LAI antipsychotics. We included data regarding participants’ clinical characteristics, dose and type of antipsychotics administered, rates of monitoring for- and rates of metabolic syndrome and individual metabolic parameters (body mass index or measure of central obesity, blood pressure, lipid levels, plasma glucose and/or HbA1C levels).</p></div><div><h3>Results</h3><p><span>Six studies were included that evaluated rates of monitoring for- and 39 studies examined rates of metabolic syndrome or individual metabolic parameters. Metabolic parameters were not routinely measured in approximately 75% of patients. Rates of metabolic syndrome ranged between 24.3% and 53.2%, with most studies finding no significant differences between oral and LAIs; however, a more preferable weight and lipid profile was detected with LAIs compared to the oral antipsychotics olanzapine and </span>clozapine. Rates of metabolic syndrome and abnormalities of metabolic parameters were comparable among first- and second-generation and between second-generation LAIs.</p></div><div><h3>Conclusions</h3><p>LAI antipsychotics are associated with high rates of metabolic syndrome but low rates of regular monitoring. A robust screening plan to monitor for metabolic syndrome in individuals treated with LAIs is advised including measurement of individual metabolic parameters.</p></div>\",\"PeriodicalId\":12045,\"journal\":{\"name\":\"European Journal of Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0213616322000027\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213616322000027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 2

摘要

背景和目的长效注射抗精神病药物可提高患者的依从性,降低复发率,并促进与社区心理健康团队的定期互动。然而,抗精神病药物与包括代谢综合征在内的不良反应有关。这篇综述概述了LAI抗精神病药物治疗患者代谢综合征的监测率和发生率。方法我们在Medline、EMBASE和Cochrane中搜索医学主题标题(MeSH)术语,包括代谢综合征或代谢综合征、仓库或LAI抗精神病药物。我们纳入了有关参与者的临床特征、服用抗精神病药物的剂量和类型的数据,代谢综合征和个体代谢参数(体重指数或中心性肥胖、血压、脂质水平、血糖和/或HbA1C水平)的监测率和监测率。结果包括6项评估监测率的研究,39项检查代谢综合征或个体代谢参数的监测率。大约75%的患者没有常规测量代谢参数。代谢综合征的发生率在24.3%至53.2%之间,大多数研究发现口服和LAI之间没有显著差异;然而,与口服抗精神病药物奥氮平和氯氮平相比,LAI检测到更优选的体重和脂质状况。第一代和第二代以及第二代LAI之间的代谢综合征发生率和代谢参数异常具有可比性。结论LAI抗精神病药物与代谢综合征的发生率高但定期监测的发生率低有关。建议制定一项强有力的筛查计划,监测接受LAI治疗的个体的代谢综合征,包括测量个体代谢参数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review

Background and Objectives

Long-acting injectable (LAI) antipsychotics increase patient adherence, reduce relapse rates and facilitate regular interaction with community mental health teams. Antipsychotics are however associated with adverse effects including metabolic syndrome. This review outlines the rates of monitoring for and rates of metabolic syndrome in patients treated with LAI antipsychotics.

Methods

We searched Medline, EMBASE, and Cochrane for Medical Subject Heading (MeSH) terms including metabolic syndrome or MetS and depot or LAI antipsychotics. We included data regarding participants’ clinical characteristics, dose and type of antipsychotics administered, rates of monitoring for- and rates of metabolic syndrome and individual metabolic parameters (body mass index or measure of central obesity, blood pressure, lipid levels, plasma glucose and/or HbA1C levels).

Results

Six studies were included that evaluated rates of monitoring for- and 39 studies examined rates of metabolic syndrome or individual metabolic parameters. Metabolic parameters were not routinely measured in approximately 75% of patients. Rates of metabolic syndrome ranged between 24.3% and 53.2%, with most studies finding no significant differences between oral and LAIs; however, a more preferable weight and lipid profile was detected with LAIs compared to the oral antipsychotics olanzapine and clozapine. Rates of metabolic syndrome and abnormalities of metabolic parameters were comparable among first- and second-generation and between second-generation LAIs.

Conclusions

LAI antipsychotics are associated with high rates of metabolic syndrome but low rates of regular monitoring. A robust screening plan to monitor for metabolic syndrome in individuals treated with LAIs is advised including measurement of individual metabolic parameters.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.90
自引率
0.00%
发文量
40
审稿时长
43 days
期刊介绍: The European journal of psychiatry is a quarterly publication founded in 1986 and directed by Professor Seva until his death in 2004. It was originally intended to report “the scientific activity of European psychiatrists” and “to bring about a greater degree of communication” among them. However, “since scientific knowledge has no geographical or cultural boundaries, is open to contributions from all over the world”. These principles are maintained in the new stage of the journal, now expanded with the help of an American editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信